Divigel 0.1%

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Divigel 0.1%

Quick Facts

Property Description
Active ingredient Estradiol (17beta-Estradiol hemihydrate)
Form Transdermal Gel (Semisolid preparation)
Pharmacological class Hormone Replacement Therapy (HRT) agent; Systemic Estrogen
Common use Estrogen replacement
Origin Bioidentical hormone

Divigel 0.1% is a prescription-only transdermal gel used as an agent for Systemic Estrogen Replacement Therapy, intended to address low levels of a key female sex hormone. The preparation is classified as a single active ingredient product (Monotherapy) within the broader pharmacological class of Estrogens. A key attribute is its unique delivery system: the transdermal gel facilitates the precise administration and controlled delivery of the hormone directly into the bloodstream through the skin, minimizing initial metabolism by the liver.

What Type of Medication is Divigel 0.1%?

Divigel 0.1% is a form of Systemic Estrogen Replacement Therapy, categorized as a specialized Hormone Replacement Therapy (HRT) agent designed to restore hormonal balance. This pharmacological classification means the medication’s primary function is to provide the body with Estradiol, a crucial hormone that it may no longer be producing adequately following menopause. This approach is clinically recognized for managing conditions linked to significant hormone deficiency. The transdermal delivery system ensures the medication is absorbed into the general circulation, establishing its crucial systemic action across the body.

Estradiol Gel: Composition and Origin of the Active Ingredient

The main component in the gel is Estradiol, specifically the 17beta-Estradiol form, which is a bioidentical hormone compound. Estradiol is chemically identical to the primary sex hormone naturally produced by the human ovaries, and the gel is formulated to deliver this component at a specific concentration of 0.1%. The preparation is housed in an alcohol-based gel base designed to facilitate consistent and controlled transdermal absorption of the Estradiol hemihydrate active substance. The application of the gel provides a distinct delivery mechanism compared to oral alternatives.

The General Purpose of Systemic Estrogen Replacement

The primary function of Divigel 0.1% is to supplement or restore circulating estrogen levels that have fallen below required physiological thresholds. This systemic action is fundamental to the drug's purpose, which is to mitigate the overall physiological effects linked to a deficiency in the female sex hormone. By replenishing the body's estrogen supply through the skin, the therapy aims to support the maintenance of hormonal balance in estrogen-dependent systems.

Regulatory References

  1. NIH MedlinePlus

What side effects are possible with Divigel 0.1%?

Possible side effects and safety information for Divigel 0.1%

The official safety profile for Divigel 0.1% (Estradiol transdermal gel) is structured by governmental regulatory agencies (such as the FDA and EMA) to communicate known adverse reactions and critical constraints for use.


Adverse Reactions and Systemic Classification

Adverse reactions are classified by frequency, with Common reactions affecting up to 1 in 10 patients. These frequently reported events include headache, nausea, breast pain or tenderness, abdominal pain, and localized application site reactions (e.g., irritation or rash). These effects are formally organized by System-Organ Classes, such as Nervous system disorders, Gastrointestinal disorders, and Reproductive system and breast disorders.

In some cases, specific adverse events like breakthrough bleeding or spotting are documented to be more common during the initial months of treatment, reflecting a time-related safety pattern.


Serious Safety Constraints

The most serious safety concerns explicitly highlighted in regulatory labeling include the risk of Venous Thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, and Arterial Thromboembolism, such as stroke and myocardial infarction. There is also an increased risk documented for certain malignancies, including Endometrial Carcinoma (in women with a uterus using estrogen alone) and Breast Cancer.

Official regulatory documents define specific safety-related restrictions and limitations (contraindications) for the medication. These include a known history of VTE, active arterial thromboembolic disease, known or suspected estrogen-dependent malignant tumors, and specific severe liver disorders. The therapy is primarily intended for use in postmenopausal women.

Overdose and Emergency Response

Overdose Scope

Category Official Regulatory Statement (Estradiol Gel)
Documented overdose presentations: Symptoms listed include Nausea, Vomiting, Breast Tenderness or pain, Abdominal Cramps, Headache, and the occurrence of Withdrawal Bleeding (menstrual-like bleeding).
Physiological systems affected: Symptoms primarily reflect effects on the gastrointestinal system, hormonal tissues, and general systemic effects, including Fluid Retention.
Population-specific overdose notes: No specific population-based considerations (e.g., pediatric or organ-impaired patients) are routinely detailed in the dedicated overdose section of the official labeling.
When medical help is required: Medical help must be sought immediately for suspected overexposure or if significant symptoms are present.

Overdose Classifications (High-Level)

Category Official Regulatory Statement (Estradiol Gel)
Severity classification: Acute overdose with Estradiol is generally classified as being of low toxicity.
Antidote Information: No specific antidote is known for overexposure.
Management Measures: Management is strictly symptomatic and supportive.

Official Overdose Statements

The regulatory documents define the overdose profile of Divigel 0.1% based on the low acute toxicity of the active substance and a cluster of reversible symptoms. The mandatory action upon suspicion of overexposure is the immediate discontinuation of the gel. Medical observation and monitoring may be required based on symptom severity, as the management relies entirely on supportive care. This classification determines that the emergency-seeking condition requires immediate product cessation and medical intervention focused on managing the documented manifestations.

Therapeutic Uses of Divigel 0.1%

Divigel 0.1% is a transdermal estradiol gel used primarily as a form of Systemic Estrogen Replacement Therapy to address the symptoms related to estrogen deficiency in postmenopausal women. The therapy is relevant for the management of symptoms related to vasomotor instability.

This medication is generally applied across domains where supportive symptomatic assistance is needed. It may assist in addressing disruptive hot flashes and night sweats, helps manage discomfort associated with vulvar and vaginal atrophy, and, in applicable clinical contexts, plays a role in the management of postmenopausal osteoporosis risk. The goal of using the therapy is often described as providing additional symptomatic support during periods of heightened symptoms.

Therapeutic Focus and Symptom Relief

Divigel 0.1% helps address symptom clusters that may become intense, particularly those that create noticeable physiological strain and interfere with daily stability. The treatment contributes to improved comfort by easing the overall symptom burden, and assists with maintaining functional stability. This supportive relief is relevant for conditions characterized by periods of heightened symptoms and is applied in scenarios where additional management of localized or systemic discomfort is required.


Quick Fact: Supportive Symptom Management The therapy is commonly used for managing symptoms that create noticeable physiological strain due to vasomotor instability, offering relief that helps patients cope more steadily with symptom fluctuations, thereby supporting general well-being.


Eligibility and Restrictions for Use

Who Can and Cannot Use Divigel 0.1%?

Divigel 0.1% eligibility is strictly defined by regulatory authorities and is limited primarily to postmenopausal women to address estrogen deficiency. The medication's label defines several major populations for whom use is absolutely contraindicated.


Populations and Conditions Prohibited from Use (Contraindicated)

Category Prohibited Condition
Cancer History Known, suspected, or history of breast cancer or estrogen-dependent neoplasia
Vascular Health Active or history of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), or arterial thromboembolic disease (e.g., stroke, MI)
Blood Disorders Known thrombophilic disorders (e.g., Protein C, S, or Antithrombin deficiency)
Organ Function Known liver impairment or disease
Other Undiagnosed abnormal genital bleeding or known hypersensitivity to the gel's components

Age and Reproductive Status Eligibility

Divigel 0.1% is not indicated for use in pediatric patients (children or adolescents). Use is strictly contraindicated during pregnancy and when breastfeeding.

For women aged 65 years and older, regulatory documents note that studies have included an insufficient number of geriatric women to determine if their response differs from younger subjects, and it is not recommended for the prevention of cardiovascular disease or probable dementia. Women with an intact uterus must use the gel in combination with a progestin.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Divigel (Estradiol Gel 0.1%) interacts with several substance classes through distinct regulatory pathways, affecting its systemic exposure and pharmacodynamic action, as documented in official prescribing information.

Pharmacokinetic Interactions (Enzyme-Mediated)

The primary interaction mechanism involves the CYP3A4 metabolic pathway. Co-administration with strong CYP3A4 inducers (e.g., Rifampin, Phenytoin, St. John's Wort) may reduce estradiol plasma concentrations, potentially diminishing the therapeutic effect. Conversely, strong CYP3A4 inhibitors (e.g., Ketoconazole, Itraconazole, Grapefruit juice) may increase estradiol plasma concentrations, raising the potential for adverse effects.

Pharmacodynamic and Topical Interactions

Estrogen therapy may diminish the therapeutic effectiveness of certain co-administered agents, including anticoagulants, antidiabetic agents, and antihypertensive agents. Systemic estrogens also increase Thyroid-Binding Globulin, which can alter laboratory values in individuals taking thyroid replacement therapy. Due to the transdermal delivery, washing the application site within one hour of use is documented to reduce systemic drug exposure by a quantified amount. The co-application of sunscreens is also noted as having the potential to alter the systemic exposure of the estradiol component.

Contraindication Related to Clearance

Although no specific drug-drug combination is formally listed as a contraindication, the use of estrogen therapy is contraindicated in individuals with liver impairment due to the officially documented risk of decreased drug clearance, which increases the potential for adverse effects.

Mechanism of Action

Divigel 0.1% contains the steroidal hormone estradiol, which, following transdermal absorption, enters the systemic circulation and distributes to estrogen-responsive tissues. Estradiol functions as an agonist for the nuclear estrogen receptors (ERalpha and ERbeta), which are primarily located in the cell nucleus. The lipophilic estradiol molecule passively diffuses across the cell membrane, binding to the intracellular ERs.

Upon ligand binding, the receptor undergoes a conformational change, dimerizes, and translocates to the nucleus. This activated receptor-ligand complex binds to specific DNA sequences known as estrogen response elements (EREs) within the promoter regions of target genes. This binding event modulates gene transcription, leading to changes in the synthesis rates of corresponding proteins. Estradiol also interacts with membrane estrogen receptors (mERs), such as GPER, to initiate rapid, non-genomic signaling cascades. These cascades involve the activation of protein kinases, including MAPK and PI3K, modifying cell function via phosphorylation events.

At a system level, these molecular interactions modulate the hypothalamic-pituitary-gonadal axis by exerting negative feedback on the pituitary gland. This action decreases the pulsatile secretion of the gonadotropins, Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH), thereby modulating their circulating levels.

Dosage and Administration Information

How to Use Divigel 0.1%: Official Administration Guidelines

Divigel 0.1% is a transdermal gel containing estradiol, intended for application to the skin, following strict administration protocols. This regimen is structured to ensure systemic delivery of the hormone while managing absorption conditions.

Official Administration Protocol

Feature Labeled Administration Principle
Route and Application Site Transdermal application to the skin of the right or left upper thigh.
Starting Dose and Frequency The usual regimen begins with 0.25 mg of estradiol (contained in 0.25 g gel) applied once daily.
Dose Adjustment Principle The dose may be adjusted based on individual response, generally up to a maximum of 1.25 mg (1.25 g gel) daily in the U.S. or up to 1.5 mg in some European regimens.
Duration Principle Therapy should adhere to the principle of using the lowest effective dose for the shortest duration consistent with treatment goals.

Required Administration Conditions and Co-Therapy

For women who have an intact uterus, the estrogen therapy must be combined with an adequate dosage of a progestogen for at least 12 to 14 consecutive days per month or cycle.

Application Procedure: The application site must be alternated daily between the upper thighs, and the gel should be spread over an area of approximately 5 by 7 inches. To ensure proper absorption, the application site must not be washed for at least 1 hour after administration. Hands must be washed immediately following the application of the gel.

Missed Dose Rule: If the scheduled daily dose is missed by more than 12 hours, the dose should be skipped and the regular dosing schedule resumed on the following day.

Recent Clinical Evidence

Divigel 0.1%: Recent Clinical Evidence

Clinical research has focused on how transdermal estradiol gel (Divigel 0.1% strength) may address symptoms of menopause, specifically vasomotor symptoms (VMS), which include hot flashes and night sweats. The gel contains estradiol, an estrogen hormone, which is absorbed through the skin.


Efficacy in Vasomotor Symptoms (VMS)

Studies have investigated the change in the frequency and severity of VMS in postmenopausal individuals receiving the estradiol gel compared to a placebo. A multi-center, double-blind, randomized, placebo-controlled trial examined the use of the gel over a period of 12 weeks.

  • Frequency: The trial data reported a statistically significant reduction in the average number of moderate-to-severe hot flashes per day in the group using the estradiol gel compared to the placebo group.
  • Severity: Measures of hot flash severity also showed a reported decrease in the active treatment group compared to baseline and to the placebo group.

Safety and Tolerability Profile

Research has explored the overall safety and tolerability profile of the transdermal gel during treatment periods. The most common adverse reactions reported in clinical trials were generally mild to moderate in severity. These included localized skin reactions at the application site, such as redness or irritation, and breast discomfort.

Transdermal delivery is being studied to determine if it maintains effective serum estradiol concentrations while potentially avoiding some of the initial hepatic (liver) metabolism associated with oral estrogen administration. However, the use of all estrogen-containing products is associated with certain risks, and potential systemic side effects were assessed across all treatment groups.

Key Studies & References

  1. Study to Evaluate Divigel for the Treatment of Postmenopausal Symptoms (ClinicalTrials.gov identifier for the pivotal 12-week trial)

Frequently Asked Questions (FAQ)

Common questions about Divigel 0.1% (FAQ)

Q: Why is Divigel applied to the skin instead of taken by mouth?

A: According to official product information, Divigel is applied to the skin because this transdermal route helps the body absorb the hormone directly into the bloodstream. This method is designed to help bypass the first-pass hepatic metabolism, which is the initial processing of the medicine by the liver that occurs with oral tablets. This delivery system is intended to provide a more stable delivery of the hormone.

Q: How soon after starting Divigel do people typically notice an improvement in symptoms?

A: Clinical trials for Divigel often assess the reduction of symptoms over a 12-week period of continuous use. While the product is officially used for symptoms that adversely affect quality of life, a specific time to initial symptom relief is not consistently defined across all regulatory documents. Individual response to therapy is highly variable.

Q: Why do some women use this gel for symptoms other than just hot flashes?

A: Official information indicates that Divigel is a form of Hormone Replacement Therapy (HRT) for estrogen deficiency symptoms in postmenopausal women. While commonly associated with hot flashes, it is also indicated for the prevention of osteoporosis (bone loss) in postmenopausal women considered to be at high risk.

Q: Can Divigel potentially affect the results of common blood tests?

A: Official labeling documents state that systemic estrogens can cause an increase in thyroid-binding globulin levels. This alteration may change the results of certain thyroid function tests. Assessing symptoms is not typically reliant on measuring serum estradiol or FSH levels.

Q: How is the estradiol from the gel absorbed into the body through the skin?

A: The estradiol from the gel is absorbed into the bloodstream through the intact skin layer, which is known as a passive absorption process. Official information indicates the absorption across the outer skin layer (stratum corneum) is the element that determines the rate at which the hormone enters the body.

Q: How long does the gel usually take to dry completely after application?

A: Official patient instructions advise allowing the gel to dry completely on the skin before covering the application site with clothing. The gel, which is an alcohol-based formula, is typically described in patient information as drying within approximately 2 minutes after application.

Q: What should be done if the gel is accidentally applied to the wrong area of the skin?

A: The official instructions specify the upper thigh/lower trunk as the correct application site and advise avoiding areas like the face, breasts, or irritated skin. If the gel is accidentally applied to an unintended area, regulatory principles suggest immediate rinsing of the gel with water.

Q: Can the application site be covered with clothing immediately after the gel dries?

A: Yes, regulatory documents advise that as soon as the gel has dried after application, which typically takes a few minutes, the application site should be covered with clothing.

Q: Will Divigel leave a noticeable residue or odor on the skin?

A: The formulation of the gel is described in regulatory documents as a clear, colorless gel. When the product has fully dried on the skin, it is described as being odorless.

Q: Is it possible for the gel to transfer to another person through skin contact?

A: Official product information indicates there is a potential for the hormone to transfer to another person through direct physical contact with the application site. To help prevent transfer, users are advised to avoid skin-to-skin contact with others until the gel has dried completely.

Q: Can other body products like lotions or perfumes be applied to the same application area?

A: Official labeling notes that the co-application of sunscreens has the potential to alter the amount of estradiol absorbed into the body. To help maintain consistent absorption, it is generally advised to avoid applying other topical products to the same area until the gel has fully dried.

Q: Is there a specific time of day that is generally considered best for applying the gel?

A: Regulatory documents state that Divigel should be applied once daily. To help maintain a consistent dosing routine and hormone levels, patients are generally advised to apply the gel at the same time each day.

Q: What is the high-level difference between Divigel and an estradiol patch?

A: Both the gel and the patch are transdermal systems, meaning they deliver the hormone through the skin. However, these systems result in different serum estradiol profiles (how the level changes in the blood) and may require individual dose adjustments based on response.

Q: Does using an alcohol-based hand sanitizer on my hands affect how the gel works?

A: The gel itself is alcohol-based to aid in absorption. Official instructions mandate that hands must be washed with soap and water immediately following application. There is no specific regulatory guidance regarding the use of hand sanitizer near the application site or time.

Q: What are the general signs that could indicate too much or too little estrogen is being absorbed?

A: Regulatory documents list certain systemic effects that may be associated with estrogen therapy. These effects can include an increase in blood pressure, new or severe migraine-like headaches, and significant fluid retention. Such effects are generally noted for discussion with a healthcare professional.

Q: Does Divigel help with psychological symptoms like low mood or irritability related to menopause?

A: Divigel is formally indicated for Hormone Replacement Therapy to address general estrogen deficiency symptoms. These symptoms can include a wide range of effects linked to hormonal changes, such as disturbed sleep.

Q: Is Divigel associated with causing changes in body weight?

A: In some official reports, weight gain has been documented as a possible side effect of the treatment. This is generally categorized as being less common in some regulatory sources.

Q: Can the gel be used if a patient has a history of high blood pressure?

A: High blood pressure (hypertension) is listed as a factor that requires attention during therapy. It is not listed as an absolute contraindication, unlike a history of blood clots or cancer.

Q: Is the efficacy of the gel affected by environmental factors like heat or humidity?

A: Official instructions mandate that the gel must be stored below 25 C (77 F). Studies have examined whether exposure to external heat (like high humidity or direct sunlight) may potentially cause an accelerated release or increased absorption of the transdermal hormone.

Q: Is there a reported difference in how quickly the gel works compared to oral estrogen tablets?

A: Pharmacokinetic studies have examined how quickly the hormone reaches its highest concentration in the bloodstream (Tmax). This time has been reported to be similar for the transdermal gel (around 4–5 hours) compared to oral estrogen tablets.

Q: Does a person's body size or weight impact how well the gel is absorbed?

A: Some clinical study data has suggested that body mass index (BMI) may be one factor considered in the therapeutic outcomes achieved by the treatment, such as the reduction in hot flash frequency and severity.

Q: What is the shelf life of Divigel once the individual pouch is opened?

A: Divigel is provided in single-dose foil pouches and is intended for immediate application as a unit dose. The official instructions state that the entire contents of the packet should be applied each day.

Q: Are there any known issues with applying the gel to skin with existing tattoos?

A: Regulatory documents advise against applying the gel to irritated skin or skin that has cuts, scrapes, or burns. While specific guidance on tattoos is not available, official instructions advise against application to broken or severely compromised skin.

Q: Is the chance of experiencing side effects the same for all approved doses of the gel?

A: The dosage of Divigel is adjusted based on individual response and is guided by the principle of using the lowest effective dose. Side effects are formally reported across the range of approved dose regimens.

Q: Does Divigel contain any parabens or common preservatives described in the official documents?

A: Official documents list the excipients (inactive ingredients) as carbomer, ethanol, propylene glycol, purified water, and triethanolamine. The product is often marketed as being free of parabens and other common preservatives.

Q: Can the gel be used to treat symptoms of menopause in younger women?

A: Official warnings note that evidence regarding risks in premature menopause is limited. However, due to the lower level of absolute risk in younger women, the balance of benefits and risks is sometimes considered to be more favorable than in older women.

Q: What are the general recommendations for traveling with Divigel, especially across different climates?

A: The primary recommendation is to adhere to the official storage requirement, which is to keep the product below 25 C (77 F). The product's packaging in individual packets is often noted as being portable for travel, provided the temperature limitation is respected.

Q: What is the function of the alcohol component in the gel formulation?

A: The gel uses an alcohol-based base. This alcohol is essential because it is designed to evaporate after application, which facilitates the consistent and controlled transdermal absorption of the estradiol through the skin into the bloodstream.

Q: Is it generally necessary to have regular check-ups while using this medication?

A: Regulatory information advises that regular medical follow-up is necessary while using this type of medication. The first visit is often recommended within 3 to 6 months of starting treatment to assess both efficacy and safety.

Q: Why is the application location typically limited to certain areas of the body?

A: The application site is limited to areas like the upper thigh and lower trunk to ensure optimal and controlled absorption of the hormone. This practice also helps to avoid direct exposure to sensitive tissues like the breasts or irritated skin.

Q: What are the descriptive terms used for the appearance and texture of the gel?

A: Official regulatory documents describe the final appearance of Divigel. It is classified as a smooth, opalescent (milky) alcohol-based gel before application.

Q: Does exercising or sweating heavily soon after application reduce the effectiveness of the gel?

A: Official labeling restricts washing the application site for at least one hour. While exercise or sweating is not explicitly restricted, excessive heat or moisture can be described as potentially affecting the absorption rates of transdermal hormones.

Q: Can using a sauna or hot tub affect the absorption of the medicine?

A: Studies on transdermal hormones indicate that exposure to direct heat, such as from a sauna or hot bath, may potentially cause an accelerated release or increased absorption of the medicine.

How should Divigel 0.1% be stored and disposed of?

Storage and Disposal Requirements

Divigel 0.1% (estradiol gel) must be stored and handled according to regulatory labeling to maintain its stability and ensure safety.

Storage/Handling Rule Requirement
Maximum Temperature Do not store above 25°C (77°F).
Child Protection Keep this medicine out of the sight and reach of children.
Flammability Warning Avoid fire, flame, or smoking until the alcohol-based gel has completely dried on the skin.
Shelf-Life Do not use the medicine after the expiry date printed on the packaging.

Official disposal rules mandate that medicines must not be thrown away via wastewater or household trash. Unused or expired product should be properly discarded by consulting a pharmacist for guidance on local pharmaceutical take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Divigel 0.1% found in:

A-Z Index: